Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06985615) titled 'A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement' on May 15.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Condition:
Hepatic Impairment
Healthy Volunteers
Intervention:
Drug: Single dose of HDM1002 on Day 1
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: March 18, 2025
Target Sample Size: 40
Countries of Recruitment:
China
To know more, visit https://clinicalt...